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Abstract
Background: Reducing women’s cardiovascular risk and the economic costs associated with cardiovascular
diseases (CVD) and diabetes (DM) continues to be a challenge. Whether a multifaceted CVD screening programme
is beneficial as a preventive strategy in women remains uncertain. The aim of this study was to investigate the
prevalence of CVD and DM as well as the acceptability toward screening and preventive actions.
Methods: An observational study was performed among all women born in 1936, 1941, 1946 and 1951 living in
Viborg Municipality, Denmark, from October 2011. In total, 1984 were invited to screening for abdominal aortic
aneurysm (AAA), peripheral arterial disease (PAD), carotid plaque (CP), hypertension (HT), atrial fibrillation (AF), DM
and dyslipidaemia. Participants with positive tests were offered prophylactic intervention including follow-up
consultations in case of AAA, PAD and/or CP. Participants with AAA ≥ 50 mm were referred to specialists in vascular
surgery. Women with AF or potential familial hypercholesterolaemia (FH) were referred to cardiology work-up.
Results: Among those invited, 1474 (74.3%) attended screening, but the attendees’ share decreased with increasing
age groups (p < 0.001). AAA was diagnosed in 10 (0.7%) women, PAD in 101 (6.9%) and CP in 602 (40.8%). The
percentage of women with these conditions rose with increasing age group (p < 0.05). Unconfirmed potential HT was
observed in 94 (6.4%), unknown AF in 6 (0.4%), DM in 14 (1%) and potential FH in 35 (2.4%). None of these findings
differed across age groups. Among the 631 women diagnosed with AAA, PAD and/or CP, 182 (28.8%) were already in
antiplatelet and 223 (35.3%) in lipid-lowering therapy prior to screening. Antiplatelet therapy was initiated in 215 (34.
1%) and lipid-lowering therapy in 191 (30.3%) women. Initiation of antiplatelet and lipid-lowering therapy was further
recommended to 134 (21.2%) and 141 (22.4%) women, respectively, who hesitated to follow the recommendation.
Conclusions: The study recorded an acceptable total attendance rate, even though a significantly lower attendance
rate was observed in the eldest women. The identified hesitation towards prophylactic therapy may affect the rationale
and effectiveness of CVD screening, and hesitation seems a critical issue that should be addressed in the design of
future screening programmes.
Keywords: Observational study, Screening, Peripheral arterial diseases, Abdominal aortic aneurysm, Diabetes mellitus
type 2, Hypertension, Atrial fibrillation, Carotid plaque
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Background
Cardiovascular diseases (CVD) and diabetes (DM) are
major causes of increased morbidity and mortality in the
Western world and much effort has been invested in de-
signing optimal and cost-effective prevention strategies.
Such strategies include early screening of at-risk popula-
tions. For example, solitary screening for abdominal aortic
aneurysm (AAA) in elderly men has been proven cost-
effective [1, 2] and has been introduced in several coun-
tries for elderly men, but not for elderly women. A com-
bined screening programme for AAA, peripheral arterial
disease (PAD) and hypertension (HT) among men aged
65–74 years demonstrated high prevalences of these dis-
eases and was beneficial for detection of prevalent cases
[3]. However, the results of that study cannot be extrapo-
lated to the general population since CVD and DM seem
to affect men and women differently. These gender differ-
ences affect the natural history of the diseases, disease
prevalences and the proportion of the population that
may benefit from initiation of prophylactic actions. Evi-
dence indicates a lower prevalence of AAA among women
than among men, whereas AAA rupture rates are almost
fourfold higher in women than in men [4], which may
counter-balance the lower prevalence from a cost-
effectiveness point of view [5]. In addition, women diag-
nosed with atrial fibrillation (AF) have a higher risk of
stroke [6]; yet women are less likely than men to receive
sufficient oral anticoagulant therapy (OAC) [7]. Further-
more, women with stroke have a poorer functional out-
come than men [8]. Similarly, women with PAD tend to
become more immobilised than men because they experi-
ence a more rapid functional decline [9]. Additionally,
women with DM have a higher risk of CVD than men
with DM [10, 11]. Gender-related differences may there-
fore hinder extrapolation of the benefits and effects of
CVD screening among men to a female population. The
aim of this screening study was to investigate the preva-
lence of CVD and DM in women as well as the acceptabil-
ity toward screening and preventive actions.
Methods
Study population
This was an observational screening study among all
women born in 1936, 1941, 1946 and 1951 living in the
Municipal of Viborg, Denmark. The study population
was identified in the Danish Civil Registration System
from October 2011 to January 2013; a total of 1984
women were included in the study.
The screening programme
The screening programme was offered within a hospital
setting. The screening tests were performed by the first
author, who had experience with CVD screening, includ-
ing ultrasonography.
A secretary sent out the invitations, which included a
plain language statement, a small questionnaire, a pre-
booked time for screening and details allowing the invi-
tees to reschedule or decline the invitation by phone,
email or surface mail. The screening sessions were
scheduled with three women per hour. Women who did
not attend their screening programme booking and had
not declined the invitation were re-invited once. Non-
responders were invited on specific days with 10 women
being booked per hour. Fridays were allocated to follow-
up on positive screening findings, including initiation of
prophylactic treatments and counselling.
Preformatted forms and questionnaires were used for
data collection. The screening programme included exam-
ination for AAA, PAD, carotid plaque (CP), HT, AF, DM
and hypercholesterolaemia/familial hypercholesterolaemia
(FH). Information was also collected concerning self-
reported medical history, lifestyle parameters, height,
weight, use of pharmacological drugs, family predisposi-
tions, walking-related pain assessed by The Walking Im-
pairment Questionnaire, and self-rated quality of life
assessed by the EuroQol’s EQ-5D-3 L.
The screening programme procedure, diagnosis criteria
and confirmation of findings
 Two-dimensional B-mode ultrasonography of the
abdominal aorta was performed in a standardised
and validated manner [12]. An inner-to-inner mea-
surrement was used during the peak of cardiac sys-
tole. AAA was defined as an anterior–posterior (AP)
aortic diameter ≥ 30 mm. AAA 30–50 mm were re-
ferred for an annual ultrasound scan and AAA ≥
50 mm for contrast computed tomography (CT) and
vascular surgical consultation. Aorta ectasia was de-
fined as an AP diameter between 25 and 29 mm.
 Ankle-brachial pressure index (ABPI) was measured
using a validated method [13]. The arm with the
highest systolic pressure was used. Arm blood
pressures (BP) were measured synchronously with
BP in the tibialis posterior and dorsalis pedis
arteries. The mean of the pedal systolic BPs was
divided by the brachial systolic pressure. This
procedure was repeated on the other leg. PAD was
defined as an ABPI < 0.9 or ≥1.4 and verified by a
re-measurement within 7–14 days.
 Two-dimensional B-mode and colour Doppler ultra-
sound imaging was performed in longitudinal and
cross-sectional mode of the common (CCA), internal
and external carotid arteries. Plaque was defined as a
focal structure that encroaches into the arterial lumen
of ≥0.5 mm or ≥50% of the surrounding vessel wall.
Furthermore, the carotid intima-media thickness
(cIMT) was measured based on the best measure
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images of the CCA far wall for each side at a plaque-
free area. However, a cIMT ≥1.5 mm was not classified
as plaque. Women with plaque were invited for a re-
scan to verify the plaque measurements.
 BP was measured synchronously in both arms. In
total, 3 BP recordings were obtained in the arm with
the highest systolic pressure. Women without
known HT and BP ≥ 160/100 mmHg were
recommended BP controls. Home measurement was
the prefered method for clarfication.
 The heart rhythm was heard in the Doppler speaker
during ABPI measurements. In case of an unknown
abnormal heart rhytm, an electrocardiogram (ECG)
was performed to identify potential AF. If the ECG
verified AF, the strategy for further investigation and
treatment was dicussed with one of the two
cardiologists in the project team.
 Glycated haemoglobin (HbA1c) was analysed at the
bedside, and DM was diagnosed if HbA1c was
≥48 mmol/mol. Women diagnosed with DM were
recommended to contact their general practiotioner
(GP) for further interventions.
 Total cholesterol (TC) was measured at the bedside. If
TC was ≥7.5 mmol/L, all lipid parameters were
measured and analysed at the laboratory.Women with
TC ≥ 7.5 mmol/L and LDL ≥ 5.5 mmol/L were referred
to further diagnostic clarification and treatment of
potential FH by a cardiologist. In case of AAA, PAD
and/or CP, statin therapy (40 mg/day simvastatin) was
recommended if TC exceeded 4.0 mmol/L.
The screening result was communicated immediately
to the participants in writing as well as verbally. Add-
itionally, the secretary informed the GPs digitally.
Women with AAA, PAD and/or CP were re-invited to
confirm the findings and provide counselling, among
others involving risk modification by encouraging the
participant to start antiplatelet and lipid-lowering ther-
apy (if these had not already been initiated or a suspi-
cion of a relative contraindication existed), physical
exercises, smoking cessation and diet. Further supportive
counselling was offered by the preventive consultants in
Viborg Municipality; the women were recommended to
bring a relative to these counselling sessions to enhance
motivation and accountability.
Statistical analysis
In Tables 1 and 2, baseline charateristics and screening
results are reported as frequencies (%) or medians with
interquartile ranges. Tests for differences across age
groups for categorical variables were analysed by the the
chi-squared (x2) test. Differences of parametric data (TC
and diastolic BP) were estimated by one-way ANOVA.
Differences of non-parametric data (Body Mass Index,
HbA1c and systolic BP) were analysed by Kruskal-Wallis
test. In Tables 3 and 4, frequencies (%) are reported. P
values in the tables refer to the used statistical test for
difference across age groups. Any p value < 0.05 was
considered statisctically significant. Data were analysed
using the software programme STATA, version 13.1
(Statacorp, College Station, TX, USA).
Table 1 Characteristics of the study population
Age group 1 (n = 592) Age group 2 (n = 622) Age group 3 (n = 433) Age group 4 (n = 337) p value
Age (years) 61 (0.8) 66 (0.8) 71 (0.9) 76 (0.8) NA
Current smoker (n) 88 (18.3) 68 (14.4) 56 (17.1) 20 (10.5) 0.062
Self-reported comorbidity (n)
Stroke 16 (3.3) 20 (4.2) 28 (8.5) 23 (12.1) < 0.001
Myocardial infarction 11 (2.3) 13 (2.7) 5 (1.5) 9 (4.7) 0.194
Diabetes mellitus 32 (6.6) 45 (9.5) 27 (8.2) 12 (6.3) 0.278
Hypertension 139 (28.8) 196 (41.4) 160 (48.8) 109 (57.4) < 0.001
Atrial fibrillation 10 (2.1) 14 (3.0) 13 (4.0) 10 (5.3) 0.151
Chronic obstructive pulmonary disease 20 (4.2) 29 (6.1) 25 (7.6) 16 (8.4) 0.136
Self-reported family predisposition (n)
Stroke 141 (29.3) 126 (26.6) 92 (28.1) 49 (25.8) 0.406
Myocardial infarction 153 (31.7) 173 (36.5) 107 (32.6) 55 (29.0) 0.392
Diabetes mellitus 97 (20.1) 103 (21.7) 83 (25.3) 36 (19.0) 0.529
Hypertension 252 (52.3) 233 (49.2) 169 (51.5) 79 (41.6) 0.329
Peripheral arterial disease 96 (19.9) 80 (16.9) 63 (19.2) 38 (20.0) 0.688
Abdominal aortic aneurysm 16 (3.3) 24 (5.1) 12 (3.7) 5 (2.6) 0.570
Except for age (n = 1984), the characteristics are available only for those who attended screening (n = 1474). Values are medians (50th centile) with interquartile
ranges or n (%). P value refers to the x2 test for difference across age groups. Family predisposition was defined as mother, father, sister or brother
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Results
In all, 1984 women were invited for screening of whom
1474 (74.3%) attended. Table 1 shows the characteristics of
the study population. The attendance rate decreased mark-
edly with age (p < 0.001). Table 2 shows the attendance rates,
the tests results and disease prevalences across age groups.
AAA, PAD and/or CP were found in 631 women. AAA
was diagnosed in 10 women (0.7%; 95% CI: 0.33; 1.24);
two AAAs were above 50 mm. The prevalence of AAA
was significantly associated with age (p = 0.025). Aortic ec-
stasies were found in 12 women (0.8%; 95% CI: 0.42; 1.42).
The mean aortic diameter for the total screened popula-
tion was 16.5 mm (95% CI: 16.3; 16.6).
PAD was diagnosed in 101 women yielding a prevalence
of 6.9% (95% CI: 5.62; 8.26); only one had an ABPI ≥1.4. In
women with a median age of 61 years, the prevalence of
PAD was 3.1%, increasing to 5.5% in age group 2, to 9.2%
in age group 3 and to 15.8% in age group 4, indicating a sig-
nificant association between PAD and age (p < 0.001). After
adjusting for smoking habits, DM, known HT, previous
stoke and myocardial infarction, the association between
PAD and age remained significant when comparing age
Table 2 Screening results
Age group 1 (n = 592) Age group 2 (n = 622) Age group 3 (n = 433) Age group 4 (n = 337) p value
Attandance (n)
At pre-booked date 382 (64.5) 400 (64.3) 272 (62.8) 154 (45.7) < 0.001
After re-scheduling 83 (14) 62 (10) 49 (11.3) 23 (6.8) 0.006
After new invitation 17 (3.5) 12 (2.5) 7 (2.1) 13 (6.8) 0.021
Total attendance 482 (81.4) 474 (76.2) 328 (75.8) 190 (56.4) < 0.001
Rejected invitation 49 (8.3) 80 (12.9) 54 (12.5) 82 (24.3) < 0.001
No response 61 (10.3) 68 (10.9) 51 (11.8) 65 (19.3) < 0.001
Test results (median)
Body Mass Index (kg/m2) 25.0 (6.4) 25.3 (6.1) 25.6 (5.5) 25.8 (5.4) 0.190
Total-cholesterol (mmol/L) 5.9 (1.3) 5.8 (1.6) 5.8 (1.5) 5.6 (1.4) 0.008
Glycated haemoglobin (mmol/mol) 34 (6) 34 (5) 35 (6) 36 (5) < 0.001
Systolic blood pressure (mmHg) 141 (26) 145 (28) 147 (25) 147 (34) < 0.001
Diastolic blood pressure (mmHg) 81 (13) 80 (13) 78 (13) 76 (14) < 0.001
Disease prevalence (n)
Abdominal aortic aneurysm 0 3 (0.6) 3 (0.9) 4 (2.1) 0.025
Aortic ectasies 1 (0.2) 3 (0.6) 7 (2.1) 1 (0.5) 0.022
Peripheral arterial disease 15 (3.1) 26 (5.5) 30 (9.2) 30 (15.8) < 0.001
Carotid plaque 148 (30.7) 188 (39.7) 161 (49.1%) 105 (55.3) < 0.001
Potential hypertension 32 (6.6) 29 (6.1) 22 (6.7) 11 (5.8) 0.964
Potential familial hypercholesterolemia 14 (2.9) 13 (2.7) 4 (1.2) 4 (2.1) 0.422
Atrial fibrillation 1 (0.2) 3 (0.6) 1 (0.3) 1 (0.5) 0.748
Diabetes mellitus 6 (1.2) 3 (0.6) 5 (1.5) 0 0.270
The test results are available only for those who attended screening (n = 1474). Values are n (%) or medians (50th centile) with interquartile ranges. For categorical
variables p value refers to the x2 test for difference across age groups. For continuous variables the p value refers to one-way ANOVA or Kruskal-Wallis test
Table 3 Status on statin therapy for women diagnosed with AAA, PAD and/or CP
Age group 1 (n = 153) Age group 2 (n = 197) Age group 3 (n = 170) Age group 4 (n = 111) p value
Already in therapy 52 (34) 65 (33) 60 (35.3) 46 (41.4) 0.493
Referred to cardiologist 6 (3.9) 7 (3.6) 4 (2.4) 1 (0.9) 0.447
Potential contraindication 1 (0.7) 1 (0.5) 2 (1.2) 0 0.670
Total cholesterol < 4.0 mmol/L 5 (3.3) 10 (5.1) 4 (2.4) 4 (3.6) 0.568
Initiation of therapy 42 (27.5) 57 (28.9) 61 (35.9) 31 (27.9) 0.312
Hesitation to accept therapy 37 (24.2) 45 (22.8) 36 (21.2) 23 (20.7) 0.890
No response 10 (6.5) 12 (6.1) 3 (1.8) 6 (5.4) 0.164
Values are n (%). P value refers to the x2 test for difference across age groups
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group 1 to age group 3 (p < 0.001) and 4 (p < 0.001). Signifi-
cant association was also found between PAD and smoking
habits (p < 0.001). Nearly half (43.6%) reported limited
walking distance with the characteristics of intermittent
claudication (95% CI: 33.7; 53.8).
CP was found in 602 women, yielding a prevalence of
40.8% (95%CI: 38.32; 43.40). The prevalence of plaque
was significantly associated with age (p < 0.001); the
prevalence increased from 30.7% in age group 1 to
55.3% in age group 4.
Some women were diagnosed with more than one condi-
tion. The presence of CP was identified in 73 of the women
with PAD (72.3%; 95% CI: 62.48; 80.72). The odds ratio for
PAD in women with plaque was 2.7 after adjusting for con-
founders (95% CI: 1.69; 4.37, p < 0.001). The mean ABPI in
women with plaque was 0.99 versus 1.05 in women without
plaque. However, in women with plaque, the mean ABPI
decreased from 1.02 in age group 1 to 0.96 in age group 4.
In women diagnosed with AAA, PAD or/and CP, 42 (6.7%)
women were found to have potential HT.
Known HT was reported by 41% (95% CI: 38.45;
43.54) and the frequency increased from 28.8% in the
youngest group to 57.4% in the oldest group of women
(p < 0.001). Possible HT based on BP ≥ 160/100 mmHg
was found in 94 women, corresponding to 6.4% of the
screened population (95% CI: 5.18; 7.75); in this group,
44 (46.8%) had verified HT above 160/100 mmHg, 19
(20.2%) had mild HT, 24 (25.5%) had normalized BP and
seven (7.4%) women missed follow-up.
Among 1414 of the attending women, 47 reported
current or previous AF, corresponding to a prevalence of
3.3% [95% CI: 2.45; 4.40]; 19 (40.4%) were currently in
OAC. Women without sufficient OAC were referred to
cardiological counselling for assessment of OAC indica-
tion. Further, six women were diagnosed with AF, corre-
sponding to 0.4% (95% CI: 0.15; 0.88).
Among 1470 of the screened women, 116 reported known
DM (7.9%; 95% CI: 6.56; 9.38). HbA1c levels ≥48 mmol/mol
were found in 14 women (1%; 95% CI: 0.52; 1.59).
Among the screened population, use of lipid-lowering
therapy was reported by 29.6% and antiplatelets like
low-dose aspirin (ASA) and clopidogrel were used by
18.3% and 2.6%, respectively. In total, 35 women (2.4%;
95% CI: 1.66; 3.29) were referred to cardiological con-
sultation for clarification of potential FH. In women di-
agnosed with AAA, PAD or/and CP (n = 631), 35.3%
received lipid-lowering therapy prior to screening. In
30.3%, statin therapy was initiated at the follow-up con-
sultation and a further 22.4% were recommended statin,
but expressed hesitation towards lipid-lowering therapy
(see Table 3 for details). In women with AAA, PAD and/
or CP, 24.3% reported receiving ASA, 5.1% clopidogrel
and 3.5% OAC prior to screening. In total, 28.8% re-
ceived one or a combination of antiplatelets. ASA was
initiated in 34.1%, and further 21.2% expressed hesita-
tion towards ASA (see Table 4 for details).
Discussion
This study represents a multifaceted screening programme
for CVD and DM in elderly women, and offers insights into
the acceptability of screening and the prevalence of these
diseases in a previously little investigated group. The study
recorded an acceptable total attendance rate of 74.3%, even
though a significantly lower attendance rate was observed
in the eldest women. The main findings were as follows:
prevalence of AAA (0.7%), PAD (6.9%), CP (40.8%), poten-
tial HT (6.4%), unknown AF (0.4%), unknown DM (1%)
and potential FH (2.4%). Lipid-lowering therapy was initi-
ated in 30.3% and antiplatelet therapy in 34.1% of the
women diagnosed with AAA, PAD and/or CP; yielding a
coverage percentage of 65.6 for lipid-lowering thearpy and
62.9 for antiplatelet therapy.
The present study illuminated multiple factors that may
affect the rationale of a combined screening programme:
1. Response rate.
Acceptance was significantly lower in the group with a
median age of 76 years. It may therefore be beneficial
to not include this age group in future screening
programmes. As the prevalence of disease increases
with age, it may therefore still make sense to extend
the offer of screening to this group despite its lower
attendance rate. Furthermore, non-attendance is re-
lated to lifestyle factors especially smoking [14]. Conse-
quently, this age group is likely to be more prone to
need prevention. The decrease in attendance rate
Table 4 Status on antiplatelet therapy for women diagnosed with AAA, PAD and/or CP
Age group 1 (n = 153) Age group 2 (n = 197) Age group 3 (n = 170) Age group 4 (n = 111) p value
Already in therapy 36 (23.5) 48 (24.4) 54 (31.8) 44 (39.6) 0.012
Referred to cardiologist 2 (1.3) 0 1 (0.6) 0 0.289
Potential contraindication 15 (9.8) 15 (7.6) 12 (7.1) 16 (14.4) 0.157
Initiation of therapy 55 (36) 69 (35) 64 (37.7) 27 (24.3) 0.112
Hesitation to accept therapy 35 (22.9) 46 (23.4) 33 (19.4) 20 (18) 0.615
No response 10 (6.5) 19 (9.6) 6 (3.5) 4 (3.6) 0.059
Values are n (%). P value refers to the x2 test for difference across age groups
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among the oldest women seems not to be gender-
specific. Hence, Lindholt et al. found similar trend
among men [15]. Alongside the screening programme,
we have interviewed 10 non-attendees to explore rea-
sons for non-attendance. Finding the screening offer
personally irrelevant was revealed as the main theme
for non-attendance. This perception was, however,
found to be changeable especially by newfound aware-
ness of the screening programme and the potential
benefits of attending [16].
2. Disease prevalence.
(a) In accordance with previous studies, we found a
lower prevalence of AAA in women than in men
[17]. Even so, screening for AAA may still be cost-
effective in women because they are at higher risk of
aneurysm rupture than men [4]. A Markov decision-
analytic model from 2006 indicated that the cost-
effectiveness of screening for AAA in female was ra-
ther insensitive to variation when the prevalence
exceeded 1% [5]. However, this calculation was made
based on a solitary screening offer and may therefore
not apply in the present study, which offered a
multifaceted screening offer. The threshold for AAA
is derived from men, where 30 mm represent an ap-
proximately 50% enlargement of the infrarenal aorta
[18]. However, gender-specific mean maximum
diameter of the aorta is considerable; in Danish eld-
erly men without and with family history of AAA,
the mean for the total screened population was
19.07 mm and 20.5 mm, respectively [19] compared
with 16.5 mm and 17.2 mm in the present study. In
case of decreasing the threshold for AAA in women
to 25 mm, the prevalence in the present study would
increase by 0.8%. Only long-term follow-up will de-
termine whether a lower threshold will compensate
for the higher rupture rate in women as well as the
clinical relevance.
(b)In Danish men who were screened for PAD, the
prevalence was 8.0% in the 65-year-olds, increasing to
15.6% in 74-year-olds. A similar age-related increase
in PAD was found in the present study: In women
with median ages of 66 and 76 years, the prevalences
of PAD were 5.5% and 15.8%, respectively.
(c)According to a systematic review, pulse palpation
has a high sensitivity, but a relatively low
specificity for identifying undiagnosed AF [20]. In
the present study, the prevalence of undiagnosed
AF was only 0.4%, which questions the efficacy of
assessment of the heart rhythm during ABPI
measurement – particularly so because the
prevalence of undiagnosed AF based on the
traditional pulse palpation approach (and ECG in
case of an irregular pulse) was 1.6% in a
population aged 65 or older [21].
(d)In the screening programme for AAA, PAD and HT
among Danish men aged 65–74 years, the
prevalence of potential HT at a cut-off value of 160/
100 mmHg was 10.5% [3] versus 6.4% in the present
study. In contrast hereto, no gender-specific differ-
ence was found in relation to self-reported, known
HT in the two Danish screening programmes.
3. The rationale of screening for CP.
CP was found in 40.8% of the women. Carotid
duplex ultrasound adds information beyond
traditional CVD risk stratification that may help to
decide the potential need for primary prevention
[22]. Evidence suggests that adding CP information
improves the CHD risk prediction [23, 24] and
statin therapy has been found to promote
delipidation of CP [25].
4. Hesitation to comply with recommended preventive
actions.
Approximately 22% of the women who were
recommended prophylactic therapy hesitated to
comply with the recommendations with a trend
towards a decrease in hesitation with older age.
Medical records showed that the women preferred to
reduce cholesterol levels through dietary changes
rather than by using medicine or discussing ASA/
statin use with their GPs. Unfortunately, no follow-up
data on adherence to follow-up at GPs are available
for the women who expressed this hesitation. The ob-
served hesitation towards prophylactic ASA/statin use
might reduce the potential health benefits of diagnos-
ing pre-manifest and manifest diseases and, conse-
quently, reduce the effectiveness of screening
programmes. However, it is likely that methods aiming
to increase acceptability could be developed, and a
focus on this issue is indicated in the future. In men
who were screened positive for PAD, hesitation to-
wards prophylactic medicine has also been reported
[3]. Whether the underlying reasons for hesitation are
gender-specific calls for further study.
5. Chosen cut-off values.
Selecting cut-off values at 140/90 mmHg for BP and
42 mmol/mol for HbA1c might lead to an unaccept-
ably high number of false-positive findings with as-
sociated psychological and societal costs. At the
mentioned cut-off values, potential HT would have
been observed in 178 women (12.1%; 95% CI: 10.46;
13.85), and 57 (3.9%; 95% CI: 2.94; 4.98) would have
been diagnosed with prediabetes based on a single
HbA1c measurement and without re-measurement
as recommended by clinical guidelines. However, the
benefit of antihypertensive treatment becomes evi-
dent at a BP above 160/100 mmHg (moderate HT)
[26] and is less clear in people without CVD and
mild HT [27, 28], suggesting that this level should
Dahl et al. BMC Cardiovascular Disorders  (2018) 18:20 Page 6 of 9
be used as a cut-off value in screening programmes.
At this somewhat higher cut-off, 94 women (6.4%)
would have been suspected of HT. Based on current
evidence, screening for prediabetes is not beneficial
in relation to reducing all-cause or cardiovascular
mortality although it is associated with a delay in
progression to DM [29].
This study informs the debate on the rationale of
screening for preclinicial and manifest CVD by substanti-
ating that such screening seems generally accepted judg-
ing by the attendance rate. The study also presents an
argument for screening for undiagnosed diseases. How-
ever, our data do not allow us to recommend a particular
preventive screening strategy. Future studies are needed
to determine how especially preclinical diseases should be
taken into account for designing cost-effective, disease-
specific preventive screening strategies. Additionally, the
identified hesitation towards prophylactic treatment needs
to be investigated further to clarify its causes and to learn
how we may address such hesitation from a gender-
specific perspective. This observed hesitation raises the
question whether prophylactic treatment is considered ac-
ceptable by the screened population and, consequently,
whether the treatment strategy fulfills the World Health
Organization’s (WHO) criteria for acceptable treatment
[30]. Furthermore, clarification of the value of adding ca-
rotid ultrasound to the CVD risk assessment as well as
management of CP as a single risk factor are required to
clarify its relevance according to the WHO’s criteria on
the importance and cost of case findings.
Limitations
Although the population-based setup and high attendance
rate make selection bias unlikely, our study had some lim-
itations, as does any other observational study. Firstly, we
used two-dimensional-based ultrasound, which may be
less effective in identifying CP than three-dimensional-
based ultrasound, and we may therefore have underesti-
mated the prevalence of plaque as suggested by the fact
that Sillesen et al. [31] found CP in 78% of asymptomatic
Americans with a mean age of 68.8 years. However, the
difference in plaque frequency between their and our
study could also be due to the definitions of plaque used.
Hence, Sillesen et al. included cIMT ≥1.5 mm in their def-
inition of plaque, whereas we did not classify cIMT
≥1.5 mm as plaque. However, in all women with cIMT
≥1.5 mm, plaque was also identified according to the
chosen plaque definitions. Secondly, comorbidities were
collected using a self-reported approach, and therefore es-
pecially the finding of insufficient OAC should be inter-
preted with caution as we did not confirm the AF
diagnosis with medical records. However, our finding of a
low adherence to OAC is in accordance with the literature
[32]. Thirdly, screening of AF was based on pulse rhythm
when measuring ABPI, which is not validated as a method
for AF screening. Fourthly, it is very likely that our study
findings cannot be fully extended to other ethnicities and
populations with other risk factor profiles such as a higher
proportion of obese people, for example. Finally, this study
cannot establish whether a screening offer like the one de-
scribed herein may be recommended as a permanent
screening offer. The best evidence for that would be
achieved through expensive, large-scaled and long-
running randomised trials. Alternatively, the experiences
gained herein may be used in models predicting the bene-
fits and cost-effectiveness of the screening offer.
Conclusion
Screening for CVD and DM is generally acceptable and
relevant for elderly women, indicating that a rationale
exists for a multifaceted screening programme. However,
the identified hesitation towards prophylactic therapy
may affect the rationale and the effectiveness of CVD
screening, and these critical issues should be addressed
in future screening programmes.
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